Skip to content

Net Income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$92.53M+37.0%
Arrowhead Research logo
Arrowhead ResearchARWR
-$137.57M-137%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$49.01M-20.1%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$2.81M-100%
Scholar Rock logo
Scholar RockSRRK
-$105.51M-41.2%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$63.73M+12.3%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.27B+153%
Enterprise value$2.69B+228%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s net income?
Dyne Therapeutics, Inc. (DYN) reported net income of -$120.85M in Q1 2026.
How has Dyne Therapeutics, Inc.'s net income changed year-over-year?
Dyne Therapeutics, Inc.'s net income decreased by 4.8% year-over-year, from -$115.36M to -$120.85M.
What is the long-term trend for Dyne Therapeutics, Inc.'s net income?
Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s net income has grown at a 31.5% compound annual growth rate (CAGR), from -$149.29M to -$446.21M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.